PlantForm Corporation’s Post

Source: Clinical and translational science A study used non-targeted metabolomics to identify plasma metabolites associated with the function of organic anion transporting polypeptide 1B1 (OATP1B1). The study analyzed fasting plasma samples from 356 healthy volunteers and identified 39 molecular features that were associated with OATP1B1 function. The strongest associations were found with two features identified as glycodeoxycholate 3-O-glucuronide (GDCA-3G) and one identified as glycochenodeoxycholate 3-O-glucuronide (GCDCA-3G). These findings confirm GDCA-3G and GCDCA-3G as robust biomarkers for OATP1B1 in human plasma.

Big shoutout to the researchers who are unlocking the secrets of mAb stability! Disulfide reduction in monoclonal antibodies (mAbs) can lead to the formation of unstable fragments (Low molecular weight Impurities), impacting patient safety and efficacy. While enzymatic mechanisms are known culprits, understanding how cellular processes during bioreactor production increase this risk after harvest has been a challenge. This new study examined mAbs from various scales (bench, pilot, and manufacturing) and identified a link: 1. Increased levels of a cellular enzyme called GAPDH and higher risk of disulfide reduction. 2. Higher GAPDH gene expression and protein levels during cell culture, and increased risk of reduction in the final product. 3. Increased G6PD activity and a shift in the lactate/pyruvate ratio, suggesting a metabolic switch towards a specific pathway (pentose phosphate pathway or PPP). What this means: Changes in cellular metabolism during production can influence protein expression and enzyme activity, ultimately impacting the risk of mAb instability. This research paves the way for better monitoring and control strategies during mAb production, ensuring higher quality and safer products for patients. #monoclonalantibodies #bioprocessing #LmW #Biomanufacturing A big thanks to the researchers for this important contribution! Let's discuss this further in the comments!

Source: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences Mycobacteria's unique lipids, particularly mycolic acids (MAs), are crucial for pathogenesis and drug resistance. Accurate MA quantification is vital for therapeutic development but faces challenges from ion suppression and lack of internal standards. This study introduces a standard addition method (SAM) using ultra-high-performance liquid chromatography-mass spectrometry to reliably quantify MAs, employing multiple reaction monitoring for specific MAs linked to tuberculosis diagnostics. The method achieves detection limits of 0.05-0.71 ng/µl and quantification limits of 0.16-2.16 ng/µl, making SAM a promising tool for medical research.

The Multifaceted Roles of Cell Growth Factors. Cell growth factors are a class of protein molecules that can promote cell growth, proliferation and differentiation. Cell growth factors play a very important role in living organisms. They promote cell proliferation and differentiation, enhance immunity, promote tissue repair and regeneration, regulate cell metabolism, and so on. #cellgrowthfactor #cellculture #cellular #biological #biopharma #biopharmaceutical #biotechnology https://lnkd.in/gum4BTXv

In vitro ADME (give rodents a break!) Are you interested in speeding up your lead optimization? So, you’ve discovered novel molecules that are potent against an exciting new biological target; now what? Will any of your molecules be able to reach the target in the context of a whole organism? To find out will certainly involve animal testing to understand in vivo pharmacokinetics and pharmacodynamics. However, testing every compound of interest in vivo is expensive and can require the sacrifice of many animals. Triaging compounds using in vitro ADME during lead optimization is more efficient and cost-effective. This approach will help your team simultaneously optimize potency and compound properties and select better compounds for in vivo studies. At GD3, we have assays for plasma protein binding, solubility, permeability, and metabolism, among others. Please speak with one of GD3’s experts to learn more about how our in vitro ADME team can advance your drug discovery and development program. Click the following link to for more information, https://lnkd.in/ezTBzjzk

In vitro ADME (give rodents a break!) Are you interested in speeding up your lead optimization? So, you’ve discovered novel molecules that are potent against an exciting new biological target; now what? Will any of your molecules be able to reach the target in the context of a whole organism? To find out will certainly involve animal testing to understand in vivo pharmacokinetics and pharmacodynamics. However, testing every compound of interest in vivo is expensive and can require the sacrifice of many animals. Triaging compounds using in vitro ADME during lead optimization is more efficient and cost-effective. This approach will help your team simultaneously optimize potency and compound properties and select better compounds for in vivo studies. At GD3, we have assays for plasma protein binding, solubility, permeability, and metabolism, among others. Please speak with one of GD3’s experts to learn more about how our in vitro ADME team can advance your drug discovery and development program. Click the following link to for more information, https://lnkd.in/ezTBzjzk

In vitro ADME (give rodents a break!) Are you interested in speeding up your lead optimization? So, you’ve discovered novel molecules that are potent against an exciting new biological target; now what? Will any of your molecules be able to reach the target in the context of a whole organism? To find out will certainly involve animal testing to understand in vivo pharmacokinetics and pharmacodynamics. However, testing every compound of interest in vivo is expensive and can require the sacrifice of many animals. Triaging compounds using in vitro ADME during lead optimization is more efficient and cost-effective. This approach will help your team simultaneously optimize potency and compound properties and select better compounds for in vivo studies. At GD3, we have assays for plasma protein binding, solubility, permeability, and metabolism, among others. Please speak with one of GD3’s experts to learn more about how our in vitro ADME team can advance your drug discovery and development program. Click the following link to for more information, https://lnkd.in/ezTBzjzk

The Future of Therapeutics with Recombinant Human Basic Fibroblast Growth Factor. As our understanding of rh-bFGF continues to expand, so does its potential in the field of therapeutics. Ongoing research aims to uncover new applications, optimize the delivery methods and improve the understanding of its mechanisms of action. With further advancements, rh-bFGF could become a cornerstone in personalized medicine, where treatments are tailored to an individual's specific needs, fostering faster and more effective healing. With ongoing research and advancements, rh-bFGF holds the potential to reshape the future of healthcare and revolutionize the way we approach various medical conditions. #biologicals #biotechnology #biopharma #geneticengineering #growthfactors #bfgf #biomedical #woundhealing https://lnkd.in/gByUbcYm

New insights into endosomal escape challenges: a path forward or an unbreakable wall? Is endosomal escape the greatest "enemy" of any genetic payload being delivered via LNPs? Maybe, if not most likely. Regardless, this process continues to impede the efficacy of LNPs from the biological and scientific point of view, since a poor understanding of the mechanisms behind it and a lack of effective measurement techniques have slowed progress in optimizing novel formulations. To bridge this knowledge gap, a quite interesting (and fun to read) study introduces a modified SNAPSwitch/SNAP-tag assay, designed specifically to assess and compare the cytosolic delivery capabilities of various LNP formulations that use ionizable lipids similar to those in major commercial products. The aim? To understand of how different LNPs perform in terms of releasing their cargo into the cytosol. So, what did the find? 1) To start, a quite surprising low endosomal escape efficiency across all tested LNP formulations, with less than 10% of the nucleic acid cargo successfully reaching the cytosol. 2) There exists a limited correlation between the volume of mRNA delivered to the cytosol and the subsequent protein expression levels, which indicates that while successful endosomal escape is necessary for initiating protein synthesis, several other subcellular processes post-delivery play crucial roles in maximizing protein expression. These 2x insights do indeed challenge the existing paradigms and underscore the need for a deeper investigation into the post-escape mechanisms that influence gene expression, since understanding these processes is essential for improving the design and formulation of the next generation of LNPs, which could significantly enhance the delivery and therapeutic efficacy of nucleic acids. Learn more here: https://lnkd.in/e5h8CfuW #Nanotechnology #Biotechnology #VaccineDevelopment #GeneTherapy #DrugDelivery #ScientificBreakthrough #HealthcareInnovation

In vitro ADME (give rodents a break!) Are you interested in speeding up your lead optimization? So, you’ve discovered novel molecules that are potent against an exciting new biological target; now what? Will any of your molecules be able to reach the target in the context of a whole organism? To find out will certainly involve animal testing to understand in vivo pharmacokinetics and pharmacodynamics. However, testing every compound of interest in vivo is expensive and can require the sacrifice of many animals. Triaging compounds using in vitro ADME during lead optimization is more efficient and cost-effective. This approach will help your team simultaneously optimize potency and compound properties and select better compounds for in vivo studies. At GD3, we have assays for plasma protein binding, solubility, permeability, and metabolism, among others. Please speak with one of GD3’s experts to learn more about how our in vitro ADME team can advance your drug discovery and development program. Click the following link to for more information, https://lnkd.in/ezTBzjzk